Home Brand News Suven Life Sciences secures Product Patents in Australia and Singapore

Suven Life Sciences secures Product Patents in Australia and Singapore

144
0

HYDERABAD, INDIA (January 16, 2019) – Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from Australia (2016217461) and one (1) product patent from Singapore (11201710044U) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036.
The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

LEAVE A REPLY

Please enter your comment!
Please enter your name here